Option chain shows key data for Quoin Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Quoin Pharmaceuticals.

Quoin Pharmaceuticals (NASDAQ:QNRX) Stock, Option Chain

Quoin Pharmaceuticals

Quoin Pharmaceuticals Ltd is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. Its pipeline comprises three products that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Epidermolysis Bullosa, and others.

movers image

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

ATNF

BREA

CLMT

CTCX

EFSH

GEVO

GRTS

KLTO

LCID

MTEM

PRQR

QNRX

SAIH

STAF

STEC

VINE

VSME

Why TSMC Shares Are Trading Higher By Around 8%; Here Are 20 Stocks Moving Premarket

oracle shutter

AMZN

ASNS

CNET

CNTM

EGIO

IONS

NUVB

ORCL

PSIG

RBRK

SGLY

SLXN

SMTK

TVGN

VRDN

WENA

WHLR

Why Oracle Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket

Earnings

Penny Stocks

Eurozone

Commodities

Small Cap

Global

Intraday Update

AISP

APGE

CNSL

DAVE

TDUP

U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 350 points on Tuesday.

The Dow traded down 0.91% to 38,633.24 while the NASDAQ fell 1.85% to 15,906.92. The S&amp;P 500 also fell, dropping, 1.05% to 5,076.98.

Crude Oil Down 1%; Dave Shares Jump After Q4 Results

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals Ltd

The agreement will see around 90% of Austrian credit institutions move their regulatory reporting infrastructure to the cloud, upgrading their legacy on-premises solution to Nasdaq AxiomSL. It reflects the growing demand for regulatory technology solutions that simplify banks' underlying architecture to more flexibly meet future requirements.

NDAQ

Nasdaq Secures Deal With AuRep To Modernize Austria's Regulatory Reporting, Powering Cloud Transformation For 90% Of Credit Institutions

Guidance

Six Flags Entertainment Sees FY25 Adj EBITDA Of $1.08B - $1.12B

Cedar Fair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUN#NYSE">FUN</a>) reported quarterly losses of $(2.76) per share which missed the analyst consensus estimate of $0.32 by 962.5 percent. This is a 1352.63 percent decrease over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $687.31 million which missed the analyst consensus estimate of $700.52 million by 1.89 percent. This is a 85.20 percent increase over sales of $371.12 million the same period last year.

Earnings Misses

Cedar Fair Q4 EPS $(2.76) Misses $0.32 Estimate, Sales $687.31M Miss $700.52M Estimate

Earnings Beats

Telefonica FY 2024 GAAP EPS €0.36 Beats €0.30 Estimate

Billionaire entrepreneur Mark Cuban has stated he will support Elon Musk — on one condition: that the Tesla Inc. CEO endorses Rep. Ro Khanna's (D-Calif.) new "Drain the Swamp" Act, which aims to curb lobbying by former White House officials.
What Happened: On Wednesday, Khanna introduced the Drain the Swamp Act, a bill that would ban White House officials from accepting gifts from lobbyists and prevent them from becoming lobbyists during Donald Trump's presidency.
&#8220;President Trump campaigned around the country to drain the swamp, yet one of the first things he did was reverse President Biden&#8217;s executive order that banned White House officials from accepting gifts from lobbyists," Khanna said.
See Also: <a href="https://in.benzinga.com/news/25/02/43974696/mark-cuban-surprisingly-loves-the-trump-administrations-push-for-ukrainian-rare-minerals-heres-why-he-thinks-its-good-for-both-sides">Mark Cuban Surprisingly &#8216;Loves&#8217; The Trump Administration&#8217;s Push For Ukrainian Rare Minerals—Here&#8217;s Why He Thinks It&#8217;s Good For Both Sides</a>
"So today I am introducing the Drain The Swamp Act … I believe that this bill will have support not just from progressives, not just from independents, but from the MAGA movement."
Cuban praised the move, calling it "so smart." He took to X, formerly Twitter, and said, "Great job @RoKhanna. Only change I would make is that it not be specific to this term. It should be permanent."
When a user on X asked, "Wait, you&#8217;re on Elon's side now?" Cuban responded: "If @elonmusk comes out and says he is for the Drain the Swamp Bill, I'm on Elon's side."
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">If <a href="https://twitter.com/elonmusk?ref_src=twsrc%5Etfw">@elonmusk</a> comes out and says he is for the Drain the Swamp Bill, I&#39;m on Elon&#39;s side <a href="https://t.co/eiz4XOjasX">https://t.co/eiz4XOjasX</a>
&mdash; Mark Cuban (@mcuban) <a href="https://twitter.com/mcuban/status/1894912768190619951?ref_src=twsrc%5Etfw">February 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It's Important: Cuban and Musk have had <a href="https://www.benzinga.com/personal-finance/25/02/43873235/not-a-lot-of-people-are-going-to-stand-up-to-him-i-dont-care-says-billionaire-mark-cuban-on-why-hes-not-afraid-to-call-out-elon-musk">their share of disagreements</a>. He once recalled Musk texting him just, &#8220;F&#x2A;&#x2A;k you,&#8221; after Cuban criticized Tesla.
Despite their clashes, Cuban recognizes Musk&#8217;s achievements. &#8220;You have to give him credit. SpaceX, Starlink, Tesla—he&#8217;s the entrepreneur of our generation.&#8221; Still, Cuban believes Musk&#8217;s sensitivity makes him an easy target.
Cuban has also criticized <a href="https://www.benzinga.com/markets/25/02/43554357/mark-cuban-calls-out-elon-musks-growing-influence-under-trump-on-a-mission-to-make-himself-above-and-beyond-the-president-of-the-united-states">Musk&#8217;s growing political ties</a>, especially his closeness to Trump. He has warned this could alienate Tesla's core audience of eco-conscious buyers.
&#8220;Anyone consider that maybe Elon's mission, is for Elon to get what he wants, rather than the country to get what you voted for,&#8221; Cuban stated at the time.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/25/02/43932776/mark-cuban-slams-fd-up-healthcare-system-blames-insurance-designed-deductibles-for-patient-bankruptcy">Mark Cuban Calls Deductibles &#8216;The Biggest Problem&#8217; in Healthcare: &#8216;System…Needs To Be Redesigned&#8217;</a></li>
</ul>
Disclaimer: This content was partially produced with the help of <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noreferrer noopener">Benzinga Neuro</a> and was reviewed and published by Benzinga editors.
Photo courtesy: Shutterstock

Government

Politics

Mark Cuban Offers Support To Elon Musk—But Only If Tesla CEO Backs Ro Khanna's Anti-Lobbying Bill

Telefónica has presented today its new financial guidance for 2025. The company forecasts year-on-year organic growth in revenue, EBITDA, and EBITDAaL-CapEx, and also sets a target for CapEx over sales below 12.5%, FCF similar to 2024 and leverage reduction. In addition, the company confirms a cash dividend of 0.30 euros per share for 2025, payable in two tranches, the first in December 2025 (0.15 euros) and the second in June 2026 (0.15 euros).

Dividends

Telefónica Projects Revenue and EBITDA Growth in 2025, Sets CapEx and Free Cash Flow Targets, Confirms 2025 Dividend Plan

Salesforce Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) unveiled its plans to aim beyond customer relationship management (CRM), addressing the trillion-dollar potential in the &#8220;digital labor revolution,&#8221; during its earnings call. The company however reported a mixed quarter, missing sales expectations.
What Happened: The &#8220;digital labor revolution&#8221; as referred to by Salesforce CEO, Marc Russell Benioff during the company&#8217;s earnings call is a transformative shift in the way work is done, driven by the rise of AI-powered digital workers or agents.
&#8220;This looks like it&#8217;s anywhere from a few trillion to 12 trillion,&#8221; said Benioff.
Highlighting this revolution as &#8220;much bigger than software,&#8221; the CEO added that he thinks building software that deploys digital workers is &#8220;more exciting&#8221;. Benioff also said that the company plans to integrate this with its &#8220;deeply unified platform&#8221;.
COO Brian Millham reiterated the CEO&#8217;s point and said, &#8220;With our deeply unified platform seamlessly integrating our Customer 360 apps, Data Cloud, and Agentforce, we&#8217;re leading the digital labor revolution.&#8221;
&#8220;When you&#8217;re the No. 1 AI CRM, you&#8217;re also going to lead the digital labor revolution,&#8221; added Benioff.
See Also: <a href="https://www.benzinga.com/25/02/43999325/snowflake-doubles-down-on-ai-expands-openai-partnership-microsoft-365-teams-to-have-new-cortex-agents">Snowflake Expands Microsoft, OpenAI Partnership: Will Include Other Prominent Models Like Anthropic&#8217;s Claude, Meta&#8217;s Llama, And DeepSeek</a>
Why It Matters: Salesforce exceeded earnings <a href="https://www.benzinga.com/news/earnings/25/02/43991325/salesforce-shares-sink-after-q4-revenues-miss-estimates-weak-fy26-guidance-details">expectations</a> but fell slightly short on revenue in its latest quarterly results. The company reported earnings of $2.78 per share, beating analyst estimates of $2.61. However, revenue reached $9.99 billion, just missing the $10.03 billion consensus forecast. Despite the slight miss, revenue still grew year-over-year, up from $9.287 billion in the same period last year. 
The company tempered expectations for fiscal year 2026 with a cautious first-quarter forecast. The company anticipates adjusted earnings per share to fall between $2.53 and $2.55, below analyst predictions of $2.61. Revenue is projected to be in the range of $9.71 billion to $9.76 billion, also lower than the $9.9 billion consensus estimate.
Price Action: CRM rose 0.47% on Wednesday and fell 5.48% in after-hours, this outpaced the 0.05% rise in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 index.
The stock remains 7.06% lower on a year-to-date basis and up 2.61% over a year.
<a href="https://www.benzinga.com/quote/CRM/analyst-ratings">Benzinga tracks 35 analysts</a> with an average price target of $378.03 for the stock, reflecting a &#8220;buy&#8221; rating. Estimates range widely from $236 to $450. Recent ratings from Citigroup, Citizens Capital Markets, and BMO Capital average $391.67, suggesting a potential 34.83% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/CRM/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="384" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27034829/CRM-ANR-1024x384.png" alt="" class="wp-image-801062" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27034829/CRM-ANR-1024x384.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27034829/CRM-ANR-300x113.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27034829/CRM-ANR-768x288.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27034829/CRM-ANR.png 1063w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43998226/jensen-huangs-nvidia-fuels-ai-factory-boom-revenue-growth-in-data-center-business-dominate">Jensen Huang&#8217;s Nvidia Fuels &#8216;AI Factory&#8217; Boom: Revenue Growth In Data Center Business Dominates Peers With A Staggering 3460% Growth Over 5 Years</a></li>
</ul>
Photo courtesy: Shutterstock

Equities

Market Summary

Broad U.S. Equity ETFs

Analyst Ratings

Salesforce Looks Beyond CRM, Bets Big On 'Digital Labor Revolution:' CEO Marc Benioff Predicts A $12 Trillion Market, Says It Is 'Much Bigger Than Software'

Telefonica FY Sales  €41.315B Beat  €40.916B Estimate

Eni Q4 EPS €0.07 Up From €0.05 YoY, Sales €23.972B Down From €24.976B YoY

Snowflake Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) unveiled its deeper partnership with Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) during its earnings call after reporting <a href="https://www.benzinga.com/news/earnings/25/02/43991826/snowflake-beats-q4-estimates-expands-microsoft-partnership-to-include-openai-models">better-than-expected</a> fourth-quarter results. The data cloud company introduced its new artificial intelligence agent Cortex for enhanced productivity and data access.
What Happened: The company announced that it has expanded its partnership with Microsoft, which brings OpenAI&#8217;s models into Cortex.
Cortex Agents are a new class of AI agents from Snowflake that can perform a variety of business tasks using structured and unstructured data. Cortex is also powered by other large language models.
&#8220;We are supporting a range of market-leading models, including Anthropic&#8217;s Claude, Meta Llama, and DeepSeek,&#8221; said CEO Sridhar Ramaswamy.
The CEO also added, &#8220;We are making Cortex Agents available in Microsoft 365 CoPilot and Microsoft Teams, bringing millions of users, seamless access to information, and accelerated productivity, all within the Microsoft platform.&#8221;
During the earnings call, Ramaswamy highlighted how AstraZeneca PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>) is using Snowflake&#8217;s AI and machine learning technology to, accelerate drug discovery and development, aiming for 20 new medicines by 2030.
He also explained that State Street Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/STT#NYSE">STT</a>) leverages Snowflake AI to uncover market insights for better investment decisions.
See Also: <a href="https://www.benzinga.com/general/market-summary/25/02/43998226/jensen-huangs-nvidia-fuels-ai-factory-boom-revenue-growth-in-data-center-business-dominates-peers-with-a-staggering-3460-growth-over-5-years">Jensen Huang&#8217;s Nvidia Fuels &#8216;AI Factory&#8217; Boom: Revenue Growth In Data Center Business Dominates Peers With A Staggering 3460% Growth Over 5 Years</a>
Why It Matters: Snowflake beat analyst expectations in its latest quarterly results. Earnings per share came in at 30 cents, significantly exceeding the 17 cents per share predicted by analysts. Revenue also soared to $986.77 million, surpassing the anticipated $955.93 million and marking a substantial jump from $774.7 million in the same period last year.
Despite the strong performance, Snowflake&#8217;s future projections fell short of analyst expectations. The company anticipates first-quarter revenue between $955 million and $960 million, lower than the $1 billion estimate. For fiscal 2026, Snowflake projects revenue of $4.28 billion, missing the $4.41 billion estimate.
Price Action: SNOW rose 1.21% on Wednesday and jumped 9.06% in after-hours, this outpaced the 0.05% rise in the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500 index.
The stock remains 5.51% higher on a year-to-date basis and down 28.99% over a year.
<a href="https://www.benzinga.com/quote/SNOW/analyst-ratings">Benzinga tracks 38 analysts</a> with an average price target of $193.42 for the stock, reflecting a &#8220;buy&#8221; rating. Estimates range widely from $121 to $235. Recent ratings from Rosenblatt, Citigroup, and Canaccord Genuity average $218.33, suggesting a potential 20.46% upside.
<figure class="wp-block-image size-large"><a href="https://www.benzinga.com/quote/SNOW/analyst-ratings"><img loading="lazy" decoding="async" width="1024" height="381" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR-1024x381.png" alt="" class="wp-image-800957" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR-1024x381.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR-300x112.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR-768x286.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27025756/SNOW-ANR.png 1059w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/25/02/43969651/billionaire-ray-dalio-says-ai-risks-totalitarian-control-or-anarchy-as-it-could-reshape-world-in-next-5-years-here-is-a-list-of-ai-linked-etfs-for-investors-to-consider">Billionaire Ray Dalio Says AI Risks &#8216;Totalitarian Control Or Anarchy&#8217; As It Could Reshape World In Next 5 Years: Here Are AI-Linked ETFs For Investors To Consider</a></li>
</ul>
Photo courtesy: Shutterstock

MSFT

SNOW

Snowflake Expands Microsoft, OpenAI Partnership: Will Include Other Prominent Models Like Anthropic's Claude, Meta's Llama, And DeepSeek

Elon Musk&#8217;s rocket manufacturing company SpaceX said on Thursday that its Starship launch vehicle is now slated to launch as soon as Monday. The rocket was <a href="https://www.benzinga.com/general/space/25/02/43934345/starship-yet-to-get-regulatory-clearance-for-upcoming-flight-but-elon-musks-spacex-hopeful-for-friday-launch">previously set to launch</a> on Friday.
What Happened: The company announced the delay in the timeline in a post on social media platform X, without providing a reason. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Now targeting to launch Starship&#39;s eighth flight test as soon as Monday, March 3 → <a href="https://t.co/alyJTRtOIP">https://t.co/alyJTRtOIP</a> <a href="https://t.co/nVu5uHMGwi">https://t.co/nVu5uHMGwi</a>
&mdash; SpaceX (@SpaceX) <a href="https://twitter.com/SpaceX/status/1894979625123799116?ref_src=twsrc%5Etfw">February 27, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: For the upcoming test flight, SpaceX is eyeing Starship's first payload deployment and experiments aimed at returning the upper stage of the two-stage vehicle to the launch site for catch. The company will also attempt to return and catch the vehicle's Super Heavy booster, failing which it will have a soft splashdown in the Gulf of America.
SpaceX will attempt to deploy four Starlink simulators on its next flight, similar in size to the next generation of Starlink satellites.
SpaceX last launched Starship on Jan. 16.&nbsp;The spacecraft lifted off from Starbase in Texas at 4:37 p.m. CT, and the vehicle booster landed back at the launch site after separation from its first stage.
The spacecraft, however,&nbsp;<a href="https://www.benzinga.com/25/01/43046722/starship-explodes-during-flight-test-elon-musk-says-success-is-uncertain-but-entertainment-is-guaranteed" target="_blank" rel="noreferrer noopener">disintegrated in space during the flight test owing to a propellant leak.</a>&nbsp;The FAA subsequently ordered an investigation into the incident following reports of public property damage in Turks and Caicos. The company is working with the FAA to either close the mishap investigation or get a green light for its next Starship flight, it said on Monday. 
The upcoming test flight would be Starship's eighth to date and second this year. SpaceX started testing Starship in April 2023.
The Starship vehicle is part of big dreams. While NASA is looking forward to landing humans back on the surface of the Moon after a gap of over 50 years with the help of a&nbsp;<a href="https://www.benzinga.com/24/11/42108681/spacex-shows-off-conceptual-version-of-starship-which-will-help-humans-land-back-on-moon-in-over-50-yrs" target="_blank" rel="noreferrer noopener">custom version of Starship</a>, Musk is dreaming of taking&nbsp;<a href="https://www.benzinga.com/news/24/09/40770222/elon-musk-sets-2026-for-starships-first-uncrewed-mars-mission-targeting-successful-landing" target="_blank" rel="noreferrer noopener">humans to the planet Mars</a>&nbsp;aboard Starship. However, the vehicle is currently in the testing and development phase.
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/02/43967170/lucids-interim-ceo-clarifies-on-peter-rawlinsons-earlier-statement-doesnt-mean-we-are-deprioritizing-our-automotive-car-business" target="_blank" rel="noreferrer noopener">Lucid's Interim CEO Clarifies On Peter Rawlinson's Earlier Statement: ‘Doesn't Mean We Are Deprioritizing Our Automotive Car Business'</a></li>
</ul>
Photo courtesy: SpaceX

SPACE

Tech

SpaceX Starship's 8th Test Flight Delayed: Now Slated For As Soon As Monday

AAON

ABCL

ACEL

ACHC

ACHR

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AUPH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

GBTG

GDEN

GDOT

GDRX

Earnings Scheduled For February 27, 2025

NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) reported fourth-quarter revenue of $39.3 billion, representing an extraordinary growth trajectory that has seen quarterly revenue multiply nearly eight times in just five years, according to data shared Wednesday by The Kobeissi Letter.
What Happened: The chipmaker&#8217;s daily revenue reached $427 million throughout the fourth quarter, with data center sales—primarily from AI-focused GPUs—surging 93% year-over-year to $35.6 billion, now accounting for over 90% of total revenue.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nvidia&#39;s, <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a>, Q4 Revenue by Year: 1. 2015: $1.4B 2. 2016: $2.2B 3. 2017: $2.9B 4. 2018: $2.2B 5. 2019: $3.1B 6. 2020: $5B 7. 2021: $7.6B 8. 2022: $6.1B 9. 2023: $22.1B 10. 2024: $39.3B Nvidia&#39;s Q4 2024 revenue of $39.3 billion is now nearly 8 TIMES higher than it was 5 years…
&mdash; The Kobeissi Letter (@KobeissiLetter) <a href="https://twitter.com/KobeissiLetter/status/1894862360029929924?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Despite beating analyst expectations with earnings per share of $0.89 versus $0.84 expected and revenue exceeding forecasts by $1 billion, NVDA shares traded slightly lower after the announcement, continuing a pattern of muted post-earnings reactions.
Analyst John Kicklighter noted that the stock exhibited &#8220;lots of volatility, but no clear direction,&#8221; with a range of approximately 8% from the spot relative to Nvidia.
RiskReversal Co-Founder Guy Adami expressed concern about potential margin deceleration, <a href="https://www.cnbc.com/video/2025/02/26/fast-money-traders-talk-nvidia-q4-results.html">telling</a> CNBC, &#8220;If margins start to decelerate, that&#8217;s when these stories typically get long in the tooth.&#8221;
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">Nvidia earnings beats versus expectations. &#8211; EPS of $0.89 vs $0.84 expected &#8211; Revenue of $39.3 Bln vs $38.3 Bln expected Lot&#39;s of volatility, but no clear direction. Range of ~8% of spot from <a href="https://twitter.com/search?q=%24NVDA&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$NVDA</a>: <a href="https://t.co/r4n2r0ZqU1">pic.twitter.com/r4n2r0ZqU1</a>
&mdash; John Kicklighter (@JohnKicklighter) <a href="https://twitter.com/JohnKicklighter/status/1894863290414535071?ref_src=twsrc%5Etfw">February 26, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Why It Matters: CEO Jensen Huang highlighted increasing computational demands in AI, saying that next-generation models require &#8220;100 times more compute&#8221; than earlier versions. He specifically cited DeepSeek&#8217;s R1, OpenAI&#8217;s GPT-4, and xAI&#8217;s Grok 3 as examples of models using <a href="https://www.benzinga.com/markets/equities/25/02/43995515/jensen-huang-says-deepseek-was-fantastic-next-gen-models-demand-100x-more-compute-as-nvidia-smashes-earnings-records">intensive reasoning processes</a>.
&#8220;DeepSeek was fantastic,&#8221; Huang said, praising its open-source reasoning model despite the company&#8217;s stock dropping 17% in January over concerns that DeepSeek had found ways to achieve better AI performance with lower infrastructure costs.
Nvidia forecasts <a href="https://www.benzinga.com/news/earnings/25/02/43991607/nvidia-q4-earnings-highlights-revenue-beat-eps-beat-demand-for-blackwell-is-amazing">first-quarter revenue</a> of $43 billion, topping estimates of $41.75 billion. Huang says Blackwell AI supercomputers saw &#8220;billions in sales&#8221; in their first quarter as the company ramped up &#8220;massive-scale production.&#8221;
NVDA currently has a consensus price target of $172.28 based on 40 analysts, with recent targets from Rosenblatt, Morgan Stanley, and Tigress Financial implying a potential 52.59% upside.
<figure class="wp-block-image aligncenter size-full is-resized"><img decoding="async" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/27023437/Screenshot-2025-02-27-at-1.03.40%E2%80%AFPM.png" alt="" class="wp-image-800908" style="width:703px;height:auto" /></figure>
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43995014/elon-musks-influence-over-the-government-set-to-increase-trump-orders-all-federal-agencies-to-appoint-a-doge-commissar">Elon Musk&#8217;s Influence Over The Government Set To Increase, Trump Orders All Federal Agencies To Appoint A DOGE Commissar</a></li>
</ul>
Image Via Shutterstock
Disclaimer:&nbsp;This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.

NVDA

Nvidia's Q4 Revenue Surges Over 78%, Nearly 8x Higher Than 5 Years Ago: Analysts Debate Stock's Next Move As Jensen Huang Says Blackwell Production Has Been Ramped Up

The Donald Trump administration is contemplating the withdrawal of a $590 million contract previously granted to&nbsp;Moderna Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>) by the Biden administration. This contract was intended for the production of a bird flu vaccine.
What Happened: The U.S. health officials are currently scrutinizing Moderna&#8217;s avian flu vaccine contract as part of a broader review of government expenditure on messenger RNA-based vaccines, <a href="https://www.benzinga.com/news/25/02/43913228/trump-team-weighs-pulling-funding-for-moderna-bird-flu-vaccine">Bloomberg</a> reported. The contract, awarded during the final days of the Biden administration, shot up Moderna&#8217;s stock within two days of the announcement on January 17.
A spokesperson from Robert F. Kennedy Jr.-led Department of Health and Human Services (HHS) communicated that the review was necessitated by &#8220;four years of the Biden administration's failed oversight.&#8221; The spokesperson acknowledged the criticality of readiness for the pandemic but also underscored the need for careful examination of vaccine production contracts.
Moderna, having successfully completed an initial trial of the bird flu vaccine last year,&nbsp;was preparing for a&nbsp;large-scale final-stage trial. However, the absence of funding might impede the trial&#8217;s progress. The company has been grappling with the need to identify new revenue streams as the sales of its COVID-19 vaccine decline and it maintains significant investments in its pipeline.
The contract was hastily approved amid apprehensions that the Trump administration might be less inclined to finance vaccine manufacturers. Moderna has also been involved in a patent dispute with the National Institutes of Health regarding its vaccine.
SEE ALSO: <a href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs">Trump Reportedly Warns Big Pharma: Move Manufacturing To US Or Face Tariffs</a>
Why It Matters: The reconsideration of funding comes at a time when the Trump administration has <a href="https://www.benzinga.com/markets/25/02/43998434/trump-team-commits-1-billion-to-combat-bird-flu-lower-egg-prices-hopefully-by-summer-says-usda">committed $1 billion </a>to fight bird flu and bring down the rising egg prices. Notably, the commitment also includes an allocation of $100 million for vaccine research, though the poultry industry is divided on its implications. 
This development also coincides with a phase when influential personalities like <a href="https://www.benzinga.com/personal-finance/25/02/43913228/bill-gates-says-next-pandemic-can-emerge-anywhere-and-the-world-isnt-prepared-we-cant-afford-to-get-caught-flat-footed-again">Bill Gates</a> have warned about the potential for new pandemics and the world&#8217;s lack of preparedness. Gates has emphasized that we cannot afford to be caught off guard again, particularly after the devastating impact of COVID-19.
Kennedy, known for his vaccine skepticism and conspiracy theories, has extended his influence globally, undermining health initiatives like vaccination and AIDS prevention, The New York Times <a href="https://www.nytimes.com/2024/11/30/world/africa/rfk-jr-kennedy-international-work-public-health-policies.html" target="_blank" rel="noreferrer noopener">reports</a>. Through his nonprofit, Children&#8217;s Health Defense, Kennedy has <a href="https://www.benzinga.com/markets/equities/24/11/42254495/trumps-hhs-pick-rfk-jr-has-a-long-history-of-challenging-global-health-policies" target="_blank" rel="noreferrer noopener">disrupted public health efforts</a> in countries like Uganda and South Africa. He has also questioned the World Health Organization and its programs for fueling global health conspiracies.
Moderna stock has plunged over 65% during the last 12 months as per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
READ MORE: <a href="https://www.benzinga.com/25/02/43998608/tesla-continuing-to-upgrade-its-headquarters-in-texas-says-exec">Elon Musk&#8217;s Tesla Upgrades Giga Texas: Driverless Cars, Cybercab Preparations, GPU Training Cluster And More</a>

MRNA

Trump's Officials To Re-Consider Moderna's $590 Million Bird Flu Vaccine Funding: RFK Jr-Led HHS Slams 'Biden Administration's Failed Oversight'

"This feedstock allocation is a vital step in our collaboration with Sipchem," said Peter Vanacker, LyondellBasell chief executive officer. "As we move forward with our joint study, with a long-term partnership in mind, we further strengthen our commitment to Saudi Arabia. Thank you to the Ministry of Energy for their support and collaboration as we build on our successful partnership. We look forward to being a larger part of the Kingdom's thriving economy, which continues to grow and provide numerous opportunities for development and innovation."

Sipchem And LyondellBasell Advance Petrochemical Ambitions With Saudi Energy Ministry's Feedstock Allocation

IPOs

Reported Earlier, Luda Technology Group Prices $10M Initial Public Offering Of 2.5M Ordinary Shares At $4/Share

VMAR

Vision Marine Signs Three-Year Exclusive Deal With STERK, Expanding European Electric Boat Market

&nbsp;Indivior PLC (Nasdaq/LSE: INDV)&nbsp;has appointed Joe Ciaffoni, currently an Independent Non-Executive Director of the Company, as Chief Executive Officer. The terms of his appointment are subject to, and effective upon, the approval by shareholders of a new remuneration policy at the Company's AGM in May 2025.

Management

INDV

Indivior Appoints Joseph Ciaffoni As New CEO, Effective Upon Shareholder Approval In May 2025

<ul>
<li>An independent Data Safety Monitoring Board (DSMB) for the Phase 3 DRAGON trial recommends trial continuation without any modifications, maintaining the sample size at 104 subjects following a planned interim efficacy analysis; trial completion expected by Q4 2025 (including a three-month follow-up period)</li>
<li>Tinlarebant has been granted Fast Track and Rare Pediatric Disease Designations in the U.S., Orphan Drug Designation in the U.S., Europe, and Japan, and the Pioneer Drug Designation in Japan for Stargardt disease, for which there are no approved treatments</li>
</ul>

BLTE

Belite Bio's Tinlarebant Trial For Stargardt Disease Advances As DSMB Recommends Continuation Without Modifications

DTEGY

Nokia and Deutsche Telekom's T Wholesale Partner To Expand Network API Market, Empowering Developers

Press Releases

Quoin Pharmaceuticals Announces Positive Interim Data from Two Ongoing Netherton Syndrome Clinical Studies

Health Care

Quoin Pharmaceuticals Announces FDA Clearance to Initiate New QRX003 Netherton Syndrome Clinical Study

Financing

Quoin Pharmaceuticals Announces Pricing of $6.8 Million Public Offering

Quoin Pharmaceuticals Announces Additional Positive Interim Data from Ongoing Open-Label Netherton Syndrome Clinical Study

General

PRISM MarketView Spotlights Quoin Pharmaceuticals CEO Dr. Michael Myers as Specialty Pharma Shares News of Highly Positive Interim Data in Most Advanced, Comprehensive Netherton Syndrome Trials

Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study

Skinvisible Reports Licensee Success in Netherton Syndrome Clinical Studies

Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome

Quoin Pharmaceuticals Launches 'NETHERTON NOW' Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure

Quoin Pharmaceuticals Launches First Episode of "NETHERTON NOW" Video Series to Raise Awareness for Netherton Syndrome

SKVI

Comments

Quoin Pharmaceuticals

Quoin Pharmaceuticals (QNRX) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga